BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 16618399)

  • 1. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M; Mary JY; Duclos B; Veyrac M; Dupas JL; Delchier JC; Laharie D; Moreau J; Cadiot G; Picon L; Bourreille A; Sobahni I; Colombel JF;
    Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T; Göke B; Sackmann M
    Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
    Navarro FA; Hanauer SB; Kirschner BS
    J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):312-8. PubMed ID: 17873743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
    Chebli JM; Gaburri PD; De Souza AF; Pinto AL; Chebli LA; Felga GE; Forn CG; Pimentel CF
    J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA
    Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
    Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in Crohn's disease: first anniversary clinical experience.
    Cohen RD; Tsang JF; Hanauer SB
    Am J Gastroenterol; 2000 Dec; 95(12):3469-77. PubMed ID: 11151879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T; Rawlins M; Kozarek R; France R; Patterson D
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study.
    Omer B; Krebs S; Omer H; Noor TO
    Phytomedicine; 2007 Feb; 14(2-3):87-95. PubMed ID: 17240130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine.
    van den Brande JM; Peppelenbosch MP; Hommes DW
    Gastroenterology; 2006 Oct; 131(4):1362-3. PubMed ID: 17030216
    [No Abstract]   [Full Text] [Related]  

  • 19. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
    Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P
    Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.